Screener
R&D
Breakdown
Segments
Bexobrutideg (NX-5948)View metric
Internal research and development expensesView metric
NX-1607View metric
Zelebrudomide (NX-2127)View metric
| Segment | Q2 '26 |
|---|---|
| Internal research and development expenses | $56.56M |
| Bexobrutideg (NX-5948) | $28.19M |
| NX-1607 | $1.74M |
| Zelebrudomide (NX-2127) | $1.17M |
| Total | $87.65M |